ACH

Accendra Health, Inc.

Fundamental data last updated:June 4, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Distribution

Exchange

NYSE

County of HQ

US

Next Earnings Date

08/10/2026

Business Summary

Accendra Health, Inc., together with its subsidiaries, operates as a healthcare solutions company worldwide. The company operates in two segments, Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment offers a portfolio of products and services to healthcare providers and manufacturers. Its portfolio of medical and surgical supplies includes branded products and its proprietary products. This segment also offers services to healthcare providers, including supplier management, analytics, inventory management, and clinical supply management; and various programs to provide outsourced logistics and marketing solutions to its suppliers. The Patient Direct segment provides products and services for in-home care and delivery across diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment. This segment also supplies a range of other home medical equipment; and patient care products, including ostomy, wound care, urology, and incontinence and other products and services. The company serves multi-facility networks of healthcare providers, independent hospitals, surgery centers, physicians' practices, and networks of hospitals directly, as well as indirectly through third-party distributors. Accendra Health, Inc. was formerly known as Owens & Minor, Inc. and changed its name Accendra Health, Inc. in December 2025. The company was founded in 1882 and is based in Glen Allen, Virginia.

 


Analyze ACH on TradingView

VALUATION

P/E

-0.21

Market Cap ($M USD)

$221.71M

Forward P/E

3.91

PEG

0.04

PRICE TO SALES

0.08

PRICE TO BOOK

-0.48

EV / EBITDA

5.97

5-Year Average P/E

Free Cash Flow Yield

-81.10%

DCF Value

$-11.09

Graham Number

N/A

Price to FCF

-1.23

EV to FCF

-11.43

Earnings Yield

-487.35%

FCF Yield

-81.10%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$14.11

Next Year EPS Growth Estimate

$0.74

Next Year Revenue Growth Estimate

$316.20B

Return on Equity (ROE)

264.54%

FREE CASH FLOW

Operating Margin

3.47%

Debt-to-Equity

-4.85

Piotroski F-Score

4

Altman Z-Score

0.36

Return on Invested Capital (ROIC)

7.77%

Current Ratio

0.49

Quick Ratio

0.43

Net Debt to EBITDA

5.33

Interest Coverage

0.69

Gross Profit margin

41.32%

FCF PER SHARE

$-2.34

REVENUE PER SHARE

$35.41

Analyze ACH on TradingView

Gainseekers Quantitative Analysis

Summary

The market seems to be mispricing Accendra Health, Inc. significantly. With a DCF value deeply negative and a Graham Number unavailable, the stock’s valuation appears precarious. Despite a forward P/E of 3.23 suggesting potential growth, the negative earnings yield and a troubling Altman Z-score of 1.15 indicate financial distress. The company’s safety and growth prospects are questionable, with the market potentially underestimating its risks. Investors should tread carefully, given these mixed signals.

AI Exposure / Tech Reliance

Operating within the Medical Distribution industry, Accendra Health is poised to leverage AI and tech advancements to streamline logistics and supply chain efficiencies. The healthcare sector's increasing reliance on data analytics and automation could provide a competitive edge. However, the company's ability to adapt will depend on its strategic investments in these technologies.

The Bull Case

For the discerning GARP investor, Accendra Health offers intriguing prospects. The company's ROIC of 0.59% and a Piotroski F-Score of 3 suggest some operational efficiency, albeit modest. Despite a negative FCF yield, the operating margin of 0.19% hints at potential pricing power. These metrics could indicate a turnaround story, where strategic improvements might unlock value.

The Bear Case

Accendra Health's structural weaknesses are glaring. The negative Price/Book ratio and a Price/Sales ratio of 0.06 highlight severe valuation concerns. Cash flow issues are underscored by a negative FCF yield and an EV to FCF of -7.29, suggesting poor cash generation. Additionally, the stock's technical position, extended 166.76% from its 52-week high, raises red flags about its current valuation.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Hold

Average Analyst Price Target

$5.25

Institutional Ownership %

1-Year Beta

1.70

Insider Buying % (6 Mo)

Distance to 52-Week High

229.88%

Distance to 52-Week Low

36.44%

EARNINGS SURPRISE %

33.33%

50-DAY SMA

$2.95

200-DAY SMA

$3.40

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.